- Home
- RDZN vs HUMA Comparison
RDZN vs HUMA Comparison
Compare RDZN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDZN | HUMA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | 308 | 184 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.7M | 155.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RDZN | HUMA |
|---|---|---|
| Price | $1.79 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 784.6K | ★ 5.8M |
| Earning Date | 02-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.77 | $444.16 |
| Revenue Next Year | $51.46 | $248.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.55 |
| 52 Week High | $2.56 | $2.93 |
Technical Indicators
Market Signals| Indicator | RDZN | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 52.96 |
| Support Level | $1.69 | $0.92 |
| Resistance Level | $1.95 | $1.30 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 37.35 | 39.30 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.